摘要
目的分析贝伐珠单抗联合紫杉醇和卡铂(TC)化疗方案对卵巢癌患者血清炎性因子及肿瘤标志物的影响。方法选取安丘市人民医院肿瘤内科2021年7年—2022年7月收治的100例卵巢癌患者为研究对象,按照随机数字表法分为两组,每组50例。对照组采用TC化疗,观察组在此基础上采用贝伐珠单抗靶向治疗。比较两组患者的肿瘤标志物水平、炎性因子水平及毒副反应发生情况。结果治疗后,观察组的糖类抗原125、肿瘤干细胞标志物CD133、肿瘤特异性生长因子、血管内皮生长因子水平均低于对照组,组间差异有统计学意义(P<0.05)。治疗后,观察组的白细胞介素-6水平低于对照组,干扰素-γ、白细胞介素-10水平均高于对照组,组间差异有统计学意义(P<0.05)。两组的毒副反应发生率比较,差异无统计学意义(P>0.05)。结论在TC化疗的基础上联合贝伐珠单抗靶向治疗能有效降低卵巢癌患者的血清肿瘤标志物水平,抑制其体内炎症反应,且患者易耐受,值得临床推广使用。
Objective To analyze the effects of bevacizumab combined with paclitaxel plus carboplatin(TC)chemotherapy on serum inflammatory factors and tumor markers in patients with ovarian cancer.Methods 100 patients with ovarian cancer admitted to the Department of Oncology of Anqiu People's Hospital from July 2021 to July 2022 were selected as the study objects and were divided into two groups according to random number table method,with 50 cases in each group.The control group received TC chemotherapy,and the observation group received bevacizumab targeted therapy on this basis.The levels of tumor markers,inflammatory factors and toxic and side effects were compared between the two groups.Results After treatment,the levels of carbohydrate antigen 125,tumor stem cell marker CD133,tumor specific growth factor and vascular endothelial growth factor in the observation group were lower than those in the control group,the differences between the groups were statistically significant(P<0.05).After treatment,the level of interleukin-6 in the observation group were lower than that in the control group,and the levels of interferon-γ and interleukin-10 were higher than those in the control group,the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion Bevacizumab targeted therapy on the basis of TC chemotherapy can effectively reduce the level of serum tumor markers in ovarian cancer patients and inhibit the inflammatory response in vivo,which is easily tolerated by patients,and is worthy of clinical promotion and use.
作者
郎晓东
王虹
朱建凤
LANG Xiaodong;WANG Hong;ZHU Jianfeng(Department of Oncology,Anqiu People's Hospital,Weifang Shandong,262100,China)
出处
《反射疗法与康复医学》
2023年第11期178-181,共4页
Reflexology And Rehabilitation Medicine
作者简介
郎晓东(1983-),男,山东潍坊人,本科,主治医师,研究方向:肿瘤内科;通信作者:朱建凤(1983-),女,山东潍坊人,本科,主治医师,研究方向:肿瘤内科,邮箱:270824889@qq.com。
